Enduring protection provided by NMITLI118RT+ and its preparation NMITLI118RT+CFM against ischemia/reperfusion injury in rats

Abstract

Withania somnifera Dunal (Ashwagandha), is an Indian medicinal plant with significant pharmacological properties. Withanolides (steroidal lactones) are the chief constituents potentially responsible for its activity. Some of its chemotypes includes NMITLI-101, NMITLI-118, NMITLI-128. The present work elaborates the optimization and development of a ready to fill capsule powder blend (NMITLI118RT+CFM) for efficient delivery of NMITLI118RT+ (a standardized extract of a new chemotype of Withania somnifera Dunal) and to investigate their protective effects against cerebral stroke in rats. NMITLI118RT+CFM was prepared by solid liquid compacting technique and filled into capsules; it was characterized on the basis of loss on drying, flow properties, IR, disintegration time, weight variation, content uniformity and DSC analysis. NMITLI118RT+ and NMITLI118RT+CFM were evaluated for biological activity utilizing middle cerebral artery occlusion model in rats. NMITLI118RT+CFM was found to be pharmaceutically acceptable. Results showed that NMITLI118RT+ and NMITLI118RT+CFM possess significant neuroprotective activity against cerebral ischemia at 50 mg kg⁻¹ in rats. NMITLI118RT+ and its pharmaceutical compositions exhibit sufficient biological promise for management of cerebral stroke. The investigation discloses potent and prudent therapeutic potential of a new formulation using standardized fraction of a new variety of Withania somnifera (NMITLI118RT+) for brain function restoration and protection from neurological failures.